Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain
Bristol-Myers Squibb $BMY has had an awfully hard time getting analysts to like the promising data they’ve published on their Opdivo/Yervoy combo for frontline lung cancer. In the face of Merck’s $MRK dominance in this critical area with their Keytruda/chemo combo, rival Bristol-Myers failed to ignite much excitement with Checkmate-227 and a target concentrating on patients with a high tumor mutation burden.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
